Home Featured Page 160

Featured

Latest

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With...

COMPASS Pathways plc to announce second quarter 2022 financial results on...

PT341 – Monnica Williams, Ph.D. – Racism, Trauma, Research, and Psychedelics

Ecstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of...

PT340 – Joost Breeksema – The Interdisciplinary Conference on Psychedelic Research...

The Doors of Expression: LSD Alters Epigenetics and Protein Induction

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

1...159160161...305 Page 160 of 305

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With...

COMPASS Pathways plc to announce second quarter 2022 financial results on...

PT341 – Monnica Williams, Ph.D. – Racism, Trauma, Research, and Psychedelics

Ecstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of...

PT340 – Joost Breeksema – The Interdisciplinary Conference on Psychedelic Research...

The Doors of Expression: LSD Alters Epigenetics and Protein Induction

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

EDITOR PICKS

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY